|
業務類別
|
Biotechnology |
|
業務概覽
|
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company. |
| 公司地址
| 14 Einstein Street, Weizmann Science Park, Ness Ziona, ISR, 7403618 |
| 電話號碼
| +972 86328500 |
| 傳真號碼
| +972 26208070 |
| 公司網頁
| https://www.enlivex.com |
| 員工數量
| 36 |
| Dr. Einat Galamidi, M.D. |
Chief Medical Officer |
-- |
30/04/2025 |
| Mr. Oren Hershkovitz, PhD |
Chief Executive Officer |
-- |
30/04/2025 |
| Ms. Shachar Shlosberger, C.P.A. |
Chief Financial Officer |
-- |
30/04/2025 |
|
|
| Mr. Andrew E. Singer |
Independent Director |
30/04/2025 |
| Dr. Roger J. Pomerantz, F.A.C.P.,M.D. |
Vice Chairman of the Board |
30/04/2025 |
| Mr. Shai Novik, M.B.A. |
Executive Chairman of the Board |
30/04/2025 |
| Dr. Abraham Havron, PhD |
Independent Director |
30/04/2025 |
| Dr. Gili Hart, PhD |
Independent Director |
30/04/2025 |
|
|
|
|
